Amgen Emerges as Potential Cytokinetics Suitor as Novartis Pulls Away: Reports
Dropping the potential Cytokinetics buy runs contrary to Novartis’ recent dealmaking frenzy, which included the acquisition of Calypso and three research collaborations.
Source: biospace.com